AzTrials
AzTrials

PainEVAPURGELNCT04736563

Evaluation of the Antalgic Effect of Puressentiel Joints and Muscles - Gel on Joint Pain of the Knee

A study testing Joint and muscle gel Puressentiel in people with Pain and Joint Pain, run by Marco Pacchioni at 1 site in France.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

This clinical trial aims to evaluate the antalgic effect of Puressentiel Joints and Muscles - Gel with 14 essential oils for 12 weeks on knee joint pain in 45 patients suffering from chronic pain related to arthritis of the knee. Read more about this study

Who is it for?
Ages 45 to 90 years
Conditions the study is for
Pain, Joint Pain
What is being tested?
Joint and muscle gel Puressentiel
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
40 participants
Where
1 siteFrance
Study dates
1 Feb 2021to 30 Jun 2021
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 45 to 90 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Subject smust be able to understand the terms of the written informed consent and must agree to date and sign it before any study procedure is carried out,
  • Patient having signed the informed consent
  • Aged 45 to 90
  • With chronic osteoarthritis of the knee
  • Patient with or without analgesic and anti-inflammatory treatment

Who cannot join

  • Patient at the stage of surgical osteoarthritis (grade 4 plus limitation of amplitude)
  • Patient with a limited walking perimeter (<100m) for any reason whatsoever
  • Patient allergic to one of the components of the study product
  • Patient not benefiting from social security
  • Patient cannot be followed for the duration of the study
  • Participation in another clinical trial within 30 days before V0
Show all 10Show fewer
  • Subjects who cannot understand or perform study procedures.
  • Pregnant or breastfeeding women
  • People with a history of convulsive or epileptic disorders
  • People allergic to salicylates.

Trial locations and contacts

1 site in 1 country.

Elisabeth Simon, MD contact

33611815878

n.barizien@hopital-foch.org

Elisabeth Simon contact

0144405528

France1 site
  • Hopital Foch

    Suresnes, 9200

    Nicolas Barizien, MD, 0611815878

Other trials in France

About this study

Official title: Evaluation of the Antalgic Effect of Puressentiel Joints and Muscles - Gel with14 Essential Oils on Joint Pain of the Knee

This clinical trial aims to evaluate the antalgic effect of Puressentiel Joints and Muscles - Gel with 14 essential oils for 12 weeks on knee joint pain in 45 patients suffering from chronic pain related to arthritis of the knee. The evaluation of the puressentiel antalgic effect Joints and Muscles - Gel with 14 essential oils will be done by an algo-functional score of WOMAC based on items of pain, joint stiffness and locomotor function (main criterion), a visual analog scale EVA (graduated from 1 to 10) of the pain by self-assessment of the patient during the consultation and the number of daily analgesics and anti-inflammatory drugs (secondary criteria).

Read the detailed description

This clinical trial aims to evaluate the antalgic effect of Puressentiel Joints and Muscles - Gel with 14 essential oils for 12 weeks on knee joint pain in 45 patients suffering from chronic pain related to arthritis of the knee. The patients included in the study will be consultants from the Department of Physical Medicine, Rehabilitation and Sports Trauma at Foch Hospital in Suresnes and will have to present chronic pain related to arthritis of the knee either with or without antalgic and anti-inflammatory treatment. The evaluation of the puressentiel antalgic effect Joints and Muscles - Gel with 14 essential oils will be evaluated by an algo-functional score of WOMAC based on items of pain, joint stiffness and locomotor function (main criterion), a visual analog scale EVA (graduated from 1 to 10) of the pain by self-assessment of the patient during each visit and the number of daily antalgic and anti-inflammatory drugs (secondary criteria).

Conditions
Pain, Joint Pain
Being tested
Joint and muscle gel Puressentiel
Keywords
Pain, Arthritis, Knee
Medical subject headings
Pain, Arthralgia, Arthritis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Joint and muscle gel PuressentielDevice

    To evaluate the antalgic effect in patients with chronic pain related to osteoarthritis of the knee when applied to the skin of Puressentiel Joints and Muscles - Gel with 14 essential oils.

Study groups in NCT04736563
Study groupRoleWhat they receive
patients with painful arthritis of the kneeExperimentalAdministration of joints and muscle gel Puressentiel containing of 14 essential oils
Receives: Device: Joint and muscle gel Puressentiel

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Womac score is the primary outcome

    Scoring pain and locomotion with a maximum score (worse of 96). A change of 16 points is considered as a significant clinical improvement

    Measured: 30 days

  2. Pain visual analog analog scale is the secondary outcome

    Scoring pain from 1 to 100 (worse)

    Measured: 30 days

Secondary outcomes (1)
  1. Pain visual analog scale

    Pain visual analog scale scored from 0 to 100(worse). A change of 10 points is considered as clinically significant

    Measured: Evaluation at inclusion and after 30 days

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted3 Feb 2021
  2. Study start1 Feb 2021 (estimated)
  3. Primary completion30 Jun 2021 (estimated)
  4. Study completion30 Jun 2021 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Model description
open single arm study
Masking
None (open label)
Enrolment
40 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04736563
Sponsor's protocol ID
Puressentiel laboratory
Acronym
EVAPURGEL
Status last verified
Feb 2021
First submitted
29 Jan 2021
Last updated
10 Feb 2021
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A study testing Joint and muscle gel Puressentiel in people with Pain and Joint Pain, run by Marco Pacchioni at 1 site in France.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 10 Feb 2021. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Elisabeth Simon, MD (33611815878, n.barizien@hopital-foch.org), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Womac score is the primary outcome (time frame: 30 days). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Feb 2021.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in